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Genome Conference Offers Insights about the Future 
of Medicine 
__________________________________________ 
 
This past fall in San Diego, California, national biomedical and healthcare experts 
gathered to tackle a tough question: Now that the Human Genome Project (HGP) has 
provided a blue-print of our genetic code, what is the future of healthcare? During 
the TJU-sponsored conference, Insights: The Human Genome Project and the Future 
of Healthcare, speakers and audience members theorized about the potential 
usefulness and impact of the human genetic code. Insights conference speakers said 
that despite the hype generated when the completion of the human genome 
sequence was announced in June 2000, we are only at the very edge of the new 
frontier of biomedical science. The purpose of the conference was to imagine what 
might come next. 
 
CONFERENCE HIGHLIGHTS:  WHAT THE EXPERTS HAVE TO SAY 
 
The diversity of the eight presenters at the Insights conference provided a broad 
view of the Human Genome Project and its implications. The group included a 
healthcare futurist, two HGP researchers, two clinical pharmacologists leading 
genomic research studies, a biotech investment expert, a former managed care 
director who made the jump to biotechnology, and a nationally known bioethicist. 
This section highlights the key messages each of the speakers offered. 
 
Predictions for the Future 
Russell C. Coile, Jr.: Senior Vice President/National Strategy Advisor, Superior 
Consultants, Plano, Texas. 
Future developments could include gene-based diagnostics, an accelerated FDA 
approval process, cell and tissue engineering for organ replacement, and microscopic 
surgery with nanotechnology robotics. 
 
The Science and History of the Human Genome Project 
George Weinstock, PhD: Co-Director, Human Genome Sequencing Center, Baylor 
College of Medicine; Department of Microbiology and Molecular Genetics, University 
of Texas-Houston Medical School.  
Gwen Acton, PhD: Assistant Director, Functional Genomics Program, Whitehead 
Institute/MIT Center for Genome Research, Cambridge, Massachusetts. 
The ultimate objective of the human genome project was “to determine the precise 
sequence of each of the 3 billion letters that make up the DNA strand.” A complete 
and accurate identification and sequence for the human genome could facilitate a 
better understanding of human life processes and offer the potential to cure many 
diseases. 
 
Applying The Human Genome Project in Clinical Pharmacology 
Scott A. Waldman, MD, PhD: Chief, Division of Clinical Pharmacology, Thomas 
Jefferson University. 
David Flockhart, MD, PhD: Director, Pharmacogenetics Core Laboratory, Division of 
Clinical Pharmacology, Georgetown University Medical Center, Washington, DC. 
The HGP provides the basis for scientific development in three major areas: (1) 
developing gene replacement therapy; (2) predicting individual patient responses to 
drugs; and (3) applying functional genomics to find new drug targets. Dr. Waldman 
Jennifer B. Koenig:  Genome Conference Offers Insights about the Future of Medicine
Health Policy Newsletter  Vol. 14, Number 2 (June 2001), Article 7
has identified a gene that is highly associated with development of cancer: the 
guanylyl cyclase C (GCC) gene. His research has potential to lead to improved 
treatments for colorectal cancer. Dr. Flockhart has focused his research on using 
genes that relate to specific drug response, identifying who is most likely to have 
positive therapeutic outcomes and, conversely, who might develop potential side 
effects from particular medications. 
 
The Human Genome Project and Managed Care 
Grant D. Lawless, MD, RPh: Thousand Oaks, California. 
Novel products created through pharmacogenomics will probably lead to novel 
pressures for payment, in large part shouldered by managed care organizations 
(MCOs). Even now, the percentage of the total healthcare dollar spent on drugs 
concerns most payers. As high-tech drugs become more available in clinical practice, 
direct drug costs and pharmacy budget costs will rise even further. Today, many 
managed care organizations are willing to pay for more expensive drugs if there is a 
guaranteed positive health outcome. In the future, pharmaceutical and biotech 
industries alike will be expected to demonstrate this same clear improvement in 
clinical medicine if high-tech genomic-based medications are to be covered. 
 
The Wall Street Perspective 
Sushant Kumar, PhD: Mehta Partners LLC New York, New York. 
From Wall Street’s perspective, biopharmaceuticals are a good business investment, 
particularly in response to today’s favorable social and economic environment. Our 
aging population will increase market demand, as will the dynamic emerging 
economies around the world. The current healthcare environment, based 
predominantly on managed care, also enhances the economic value of 
pharmaceuticals: MCOs rely heavily on drugs as their most cost-effective care 
option. 
 
Ethical Issues 
Paul R.Wolpe, PhD: Faculty Associate, Center for Bioethics, University of 
Pennsylvania; Chief Bioethicist, National Aeronautics and Space Administration 
(NASA).  
 The public understands that genomics is going to be significantly beneficial, but they 
also fear that the thought leaders driving the genomic revolution do not recognize 
any downside of the science they are creating. The public is deeply ambivalent about 
genetic advancement. There are five primary fears the public harbors concerning 
genetic research: 
 
1. Genomics has the potential to harm individuals and society. 
 
2. Genomics will give rise to new forms of discrimination. 
 
3. Genomics will jeopardize individual rights to privacy and confidentiality. 
 
4. Genomics will result in detrimental environmental impacts. 
 
5. Genomics will exceed the limits of acceptable human intervention. 
 
Whether these fears are realized will be determined by how the ethics of genomics 
are handled by everyone involved. Dr. Wolpe believes that the time for prophylactic 
ethics is now. 
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Copies of the proceedings are available by request. Please contact The Office of 
Health Policy and Clinical Outcomes at (215) 955-6969. 
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